Zarxio (filgrastim-sndz), a biosimilar of filgrastim, is efficient and well tolerated for the prophylaxis of chemotherapy-induced neutropenia in patients with cancer in routine practice, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.1
Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer therapy, but prophylactic treatment with granulocyte-colony stimulating factor reduces the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in at-risk patients.
For the observational, prospective, longitudinal, multicenter study, researchers in France sought to evaluate the efficacy, safety, and use of Zarxio (marketed as Zarzio in France and many other countries) for the prevention of chemotherapy-induced neutropenia in 184 real-life patients with solid tumors or non-Hodgkin lymphoma. Researchers evaluated the incidence of neutropenia at each chemotherapy cycle.
Results showed that the risk of febrile neutropenia was more than 20% of 32.1% of patients, but no patients developed febrile neutropenia. Researchers found that 10 patients were hospitalized and/or received antibiotic therapy due to neutropenia.
In regard to safety, the most frequent adverse event associated with Zarxio use was pain, particularly bone pain, and no serious adverse event related to Zarxio prophylaxis was reported.
Zarxio is the first biosimilar product approved in the United States. It is approved for the same indications as filgrastim (Neupogen) and can be prescribed for patients with cancer receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, patients with cancer undergoing bone marrow transplantation, and patients undergoing autologous peripheral blood progenitor cell collection and therapy.
1. Nahon S, Rastkhah M, Abdelghani MB, et al. Zarzio, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study [published online ahead of print October 27, 2015]. Support Care Cancer. doi:10.1007/s00520-015-2986-0.